BioNTech

BNTX

Market cap $26B

Zoetis has strong growth prospects and an attractive income program. BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress.

BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.

Vaccine makers Pfizer ‌and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment ​in the trials had been too low to generate ​the needed data.

The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.

MAINZ, Germany, March 24, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data from its diversified portfolio in the field of lung cancer at the European Lung Cancer Congress (“ELCC”) held in Copenhagen, Denmark, from March 25-28, 2026. The data updates covered in both oral and poster presentations highlight progress across late-stage immunomodulator candidates pumitamig and gotistobart, as well as antibody-drug conjugate (“ADC”) programs, across various lung cancer subtypes and lines of treatment. BioNTech's clinical portfolio encompasses both monotherapies and combinations with standard of care treatments, as well as novel-novel combination regimens aimed at delivering differentiated therapeutic profiles for the treatment of patients with lung cancer across all stages of the disease.

BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript

The company guided 2026 total revenue to roughly $2.2–$2.5 billion, below Street expectations, stating that Covid will be a smaller contributor going forward and growth will depend increasingly on the oncology pipeline.

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of BioNTech SE (NASDAQ: BNTX). The investigation focuses on BioNTech's executive officers and whether investor losses may be recovered under federal securities laws.

BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock crashed more than 20%, mostly because its cofounders, Ugur Sahin (CEO) and Ozlem Tureci (CMO), said they would depart to set up a new biotech firm at the end of 2026.

BioNTech stock crumbled Tuesday after the cofounders of the German biotech announced their plan to step down.